Food and Drug Regulations (C.R.C., c. 870)
Full Document:
- HTMLFull Document: Food and Drug Regulations (Accessibility Buttons available) |
- XMLFull Document: Food and Drug Regulations [4169 KB] |
- PDFFull Document: Food and Drug Regulations [6083 KB]
Regulations are current to 2021-03-23 and last amended on 2021-03-18. Previous Versions
PART CDrugs (continued)
DIVISION 1 (continued)
Assessments Ordered Under Section 21.31 of the Act
C.01.052 (1) The Minister’s power to make an order under section 21.31 of the Act is subject to the following conditions:
(a) the order shall relate to a drug;
(b) the person to whom the order is made shall be the holder of one or more of the following therapeutic product authorizations in respect of the drug:
(c) the Minister shall have reasonable grounds to believe that
(i) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(i) or (iii), the benefits or risks of injury to health associated with the drug are significantly different than they were when the authorization was issued,
(ii) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(ii) who is an importer, the manner in which one or more of the following activities is conducted may present a risk of injury to health associated with the drug:
(iii) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(ii) other than an importer, the manner in which an activity that is authorized under the authorization is conducted may present a risk of injury to health associated with the drug.
(2) The Minister shall, after examining the results of an assessment that was ordered under section 21.31 of the Act,
(a) provide the holder of the therapeutic product authorization with the results of the examination; and
(b) ensure that a summary of the results of the examination, together with a description of any steps that the Minister has taken or may take as a consequence of the examination, is published on the Government of Canada website.
- SOR/2018-84, s. 3
Activities Ordered Under Section 21.32 of the Act
C.01.053 The Minister’s power to make an order under section 21.32 of the Act is subject to the following conditions:
(a) the order shall relate to a drug;
(b) the person to whom the order is made shall be the holder of one or more of the following therapeutic product authorizations in respect of the drug:
(c) the Minister shall have reasonable grounds to believe that
(i) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(i) or (iii), there are significant uncertainties relating to the benefits or harms associated with the drug,
(ii) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(ii) who is an importer, the manner in which one or more of the following activities is conducted has introduced significant uncertainties relating to the benefits or harms associated with the drug:
(iii) in the case of a holder of a therapeutic product authorization referred to in subparagraph (b)(ii) other than an importer, the manner in which an activity that is authorized under the authorization is conducted has introduced significant uncertainties relating to the benefits or harms associated with the drug,
(iv) the holder of the therapeutic product authorization is unable to provide the Minister with information that is sufficient to manage those uncertainties, and
(v) the applicable requirements of these Regulations, together with any terms and conditions that have been imposed on the authorization, do not allow for sufficient information to be obtained to manage those uncertainties; and
(d) the Minister shall take into account the following matters:
- SOR/2018-84, s. 3
C.01.055 and C.01.056 [Repealed, SOR/82-524, s. 2]
Limits of Variability
C.01.061 (1) Where the net amount of a drug in a package is not expressed on the label in terms of number of dosage units, any 10 packages of the drug selected as provided by official method DO-31, Determination of Net Contents, dated December 7, 1988, shall contain an amount of the drug such that, when determined by that official method, the average of the net amounts of the drug in the 10 packages is not less than the net amount of the drug shown on the label.
(2) Where the net amount of a drug in a package is expressed on the label in terms of the number of dosage units, any 10 packages of the drug selected as provided by official method DO-31, Determination of Net Contents, dated December 7, 1988, shall contain a number of units such that, when determined by that official method,
(a) the average number of dosage units in the 10 packages is not less than the number of dosage units shown on the label;
(b) no package contains less than the number of dosage units shown on the label except as provided in the table; and
(c) where the drug is a controlled drug as defined in section G.01.001 or a narcotic as defined in the Narcotic Control Regulations, no package contains more than the number of dosage units shown on the label except as provided in the table to this section.
TABLE
Item Column I Column II Labelled Number of Dosage Units Per Package Permitted Variation from the Labelled Number 1 50 or less 0 2 More than 50, but less than 101 1 3 101 or more the greater of one unit or 0.75% of the labelled number, rounded up to the next whole number
- SOR/82-429, s. 4
- SOR/89-455, s. 4
- SOR/97-228, s. 3
- SOR/2019-171, s. 24
C.01.062 (1) Subject to subsections (2) to (5), no manufacturer shall sell a drug in dosage form where the amount of any medicinal ingredient therein, determined using an acceptable method, is
(2) Subject to subsection (5), where a drug in dosage form contains a medicinal ingredient that is a volatile substance of botanical origin or its synthetic equivalent, the amount of that ingredient, determined using an acceptable method, shall be
(3) Subject to subsection (5), where a drug in capsule form contains a medicinal ingredient that is a vitamin in a fish-liver oil, no variation from the amount of the medicinal ingredient as shown on the label, determined using an acceptable method, is permitted other than that which is in accordance with the variation for that fish-liver oil as stated in any publication whose name is referred to in Schedule B to the Act.
(4) Subject to subsection (5), where a drug in dosage form contains a medicinal ingredient that is a vitamin, no variation from the amount of the medicinal ingredient shown on the label, determined using an acceptable method, is permitted other than the variation set out in column III or IV of an item of the table to this section opposite the vitamin set out in column I of that item for the amount of vitamin set out in column II of that item.
(5) Subsections (1) to (4) do not apply in respect of
(a) a drug for which a notice of compliance has been issued under section C.08.004 or C.08.004.01;
(b) [Repealed, SOR/98-423, s. 8]
(c) a drug for which a standard is contained in any publication whose name is referred to in Schedule B to the Act;
(d) a drug described in Schedule C or D to the Act or Division 6 of Part C of these Regulations; or
(e) a drug for which a drug identification number has been assigned under subsection C.01.014.2(1) and in respect of which
(i) the conditions of pharmaceutical production and quality control are suitable for controlling the identity, quality, purity, stability, safety, strength and potency of the drug,
(ii) all labels to be used in connection with the drug, including any package insert and any document that is provided on request and that sets out supplementary information on the use of the drug, make proper claims in respect of the drug,
(iii) the drug can, without undue foreseeable risk to humans, be used for the purposes and under the conditions of use recommended by the manufacturer, and
(iv) the drug is effective for the purposes and under the conditions of use recommended by the manufacturer.
TABLE
Item Column I Column II Column III Column IV Vitamin Recommended daily dose Limits of variation when the recommended daily dose shown on label is equal to or less then amount set out in column II Limits of variation when the recommended daily dose shown on label is greater than amount set out in column II 1 vitamin A (or as B-carotene) 10 000 I.U. 90.0 - 165.0 % 90.0 - 115.0 % 2 thiamine 4.5 mg 90.0 - 145.0 % 90.0 - 125.0 % 3 riboflavin 7.5 mg 90.0 - 125.0 % 90.0 - 125.0 % 4 niacin or niacinamide 45 mg 90.0 - 125.0 % 90.0 - 125.0 % 5 pyridoxine 3 mg 90.0 - 125.0 % 90.0 - 125.0 % 6 d-pantothenic acid 15 mg 90.0 - 135.0 % 90.0 - 125.0 % 7 folic acid 0.4 mg 90.0 - 135.0 % 90.0 - 115.0 % 8 vitamin B12 14 µg 90.0 - 135.0 % 90.0 - 125.0 % 9 vitamin C 150 I.U. 90.0 - 145.0 % 90.0 - 125.0 % 10 vitamin D 400 I.U. 90.0 - 145.0 % 90.0 - 115.0 % 11 vitamin E 25 I.U. 90.0 - 125.0 % 90.0 - 125.0 % 12 vitamin K 0.0 mg 90.0 - 115.0 % 13 biotin 0.0 mg 90.0 - 135.0 %
- SOR/92-131, s. 1
- SOR/92-591, s. 2
- SOR/94-689, s. 2(E)
- SOR/95-530, s. 2
- SOR/98-423, s. 8
- SOR/2011-88, s. 5
- SOR/2014-158, s. 9
- SOR/2018-69, s. 19(F)
- Date modified: